Diagnostic performance of CT/MRI LI-RADS v2018 in non-cirrhotic steatotic liver disease
European Radiology · 2024
DOI: 10.1007/s00330-024-10846-w ↗Kurz gefasst
Fachartikel in der Zeitschrift European Radiology, 2024. Verfasst von Jennie Cao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA, 94305, USA. Hauptthemen laut MEDLINE: Magnetic Resonance Imaging, Tomography, X-Ray Computed, Sensitivity and Specificity, Liver Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: To assess the performance of computed tomography (CT)/magnetic resonance imaging (MRI) Liver Imaging Reporting and Data System (LI-RADS) among patients with non-cirrhotic steatotic liver disease (SLD). MATERIALS AND METHODS: This IRB-approved, retrospective study included 119 observations from 77 adult patients (36 women, 41 men; median 64 years) who underwent liver CT or MRI from 2010 to 2023. All patients had histopathologic evidence of SLD without cirrhosis. Three board-certified abdominal radiologists blinded to tissue diagnosis and imaging follow-up assessed observations with LI-RADS. The positive predictive value (PPV), sensitivity, specificity, accuracy, and inter-reader agreement were calculated. RESULTS: Seventy-five observations (63%) were benign and 44 (37%) were malignant. PPV for hepatocellular carcinoma (HCC) was 0-0% for LR-1, 0-0% for LR-2, 0-7% for LR-3, 11-20% for LR-4, 75-88% for LR-5, 0-8% for LR-M, and 50-75% for LR-TIV. For LR-5 in identifying HCC, sensitivity was 79-83%, specificity was 91-97%, and accuracy was 89-92%. For composite categories of LR-5, LR-M, or LR-TIV in identifying malignancy, sensitivity was 86-89%, specificity was 85-96%, and accuracy was 86-93%. The most common false positives for LR-5 were hepatocellular adenomas. Only 59-65% of HCCs showed non-peripheral washout at CT versus 67-83% at MRI, though nearly all had an enhancing capsule. PPV and accuracy of LR-5 for HCC did not differ by modality. Inter-reader agreement for major features ranged from 0.667 to 0.830 and was 0.766 for the final category. CONCLUSION: Despite challenges such as the lower prevalence of non-peripheral washout at CT and overlapping imaging features between HCC and hepatocellular adenomas, LI-RADS may serve as an effective tool in assessing focal liver lesions in SLD. CLINICAL RELEVANCE STATEMENT: LI-RADS in non-cirrhotic steatotic liver disease can effectively diagnose hepatocellular carcinoma and malignancy at computed tomography and magnetic resonance imaging, thereby guiding clinical management decisions and expediting patient care pathways. KEY POINTS: Performance of LI-RADS is unknown in non-cirrhotic patients with steatotic liver disease. LI-RADS 5 category showed a high pooled specificity of 91-97% for hepatocellular carcinoma. LI-RADS can non-invasively risk stratify focal liver observations in non-cirrhotic patients with steatotic liver disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA, 94305, USA.
- Department of Radiology, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA, 94305, USA. jrtse@stanford.edu.
Zitieren
APA
Cao, J., Shon, A., Yoon, L., Kamaya, A., & Tse, J. R. (2024). Diagnostic performance of CT/MRI LI-RADS v2018 in non-cirrhotic steatotic liver disease. European Radiology. https://doi.org/10.1007/s00330-024-10846-w
Vancouver
Cao J, Shon A, Yoon L, Kamaya A, Tse JR. Diagnostic performance of CT/MRI LI-RADS v2018 in non-cirrhotic steatotic liver disease. European Radiology. 2024. doi:10.1007/s00330-024-10846-w
BibTeX
@article{Cao2024,
author = {Cao, Jennie and Shon, Andy and Yoon, Luke and Kamaya, Aya and Tse, Justin R},
title = {Diagnostic performance of CT/MRI LI-RADS v2018 in non-cirrhotic steatotic liver disease},
journal = {European Radiology},
year = {2024},
doi = {10.1007/s00330-024-10846-w}
}
EUVIMED